ResearcherOsaka International Cancer InstituteActive in the last 2 years
Takumi Kinomoto
Matched on OpenAlex author ID A5009919223. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2025: 1 paper · 2026: 2 papers
Papers 3
- Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment. Co-author DOI 10.1002/cnr2.70492↗
- Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Co-author DOI 10.1007/s10147-026-03071-6↗
- Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01309-6↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kenji Ikezawa · 3 shared papers, 2025–2026 · strength 0.71
- Paper Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the… DOI 10.1002/cnr2.70492↗
- Paper Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel f… DOI 10.1007/s10147-026-03071-6↗
- Paper Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. DOI 10.1007/s12029-025-01309-6↗
- Ryoji Takada · 3 shared papers, 2025–2026 · strength 0.71
- Paper Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the… DOI 10.1002/cnr2.70492↗
- Paper Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel f… DOI 10.1007/s10147-026-03071-6↗
- Paper Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. DOI 10.1007/s12029-025-01309-6↗
- Yugo Kai · 3 shared papers, 2025–2026 · strength 0.71
- Paper Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the… DOI 10.1002/cnr2.70492↗
- Paper Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel f… DOI 10.1007/s10147-026-03071-6↗
- Paper Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. DOI 10.1007/s12029-025-01309-6↗
- Makiko Urabe · 3 shared papers, 2025–2026 · strength 0.71
- Paper Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the… DOI 10.1002/cnr2.70492↗
- Paper Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel f… DOI 10.1007/s10147-026-03071-6↗
- Paper Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. DOI 10.1007/s12029-025-01309-6↗
- Kazuyoshi Ohkawa · 3 shared papers, 2025–2026 · strength 0.71
- Paper Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the… DOI 10.1002/cnr2.70492↗
- Paper Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel f… DOI 10.1007/s10147-026-03071-6↗
- Paper Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. DOI 10.1007/s12029-025-01309-6↗
- Kana Hosokawa · 2 shared papers, 2025–2026 · strength 0.47
- Paper Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the… DOI 10.1002/cnr2.70492↗
- Paper Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. DOI 10.1007/s12029-025-01309-6↗
- Hirofumi Akita · 1 shared paper, 2026 · strength 0.24
- Kunihito Gotoh · 1 shared paper, 2026 · strength 0.24
- Hidenori Takahashi · 1 shared paper, 2026 · strength 0.24
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.